Nelson Advisors: The introduction of Ultrahuman Heart Scan illustrates broader trends in the wearable technology and decentralised healthcare markets
Technical and Clinical Evaluation of Ultrahuman Heart Scan and FibriCheck Integration
The integration of point-in-time cardiac rhythm assessments into consumer smart rings represents a notable structural evolution in decentralised health tracking. Ultrahuman has launched Heart Scan, an on-demand heart check in capability developed for its smart ring portfolio, including the Ring PRO and Ring AIR. Powered by algorithmic software from Belgian digital health firm Qompium NV, operating
commercially as FibriCheck, Heart Scan enables users to initiate a 60 second optical pulse recording to assess rhythm regularity and screen for potential signs of atrial fibrillation (AFib) at no additional charge.
While consumer wearables have historically prioritised passive, continuous nocturnal telemetry, episodic symptomatic evaluations address the diagnostic challenge of capturing transient, paroxysmal arrhythmias. By deploying a clinical grade Software as a Medical Device (SaMD) layer over consumer tier hardware, this implementation illustrates the operational potential, physiological complexities and regulatory boundaries that define modern digital cardiovascular diagnostics.
System Specifications and Operational Architecture
Heart Scan utilises optical photoplethysmography (PPG) to track volumetric changes within the microvascular beds of the finger. Light emitting diodes (LEDs) integrated into the inner band of the Ultrahuman Ring PRO project light through the epidermal and dermal layers into the palmar digital arteries, where blood volume pulsations modulate the reflected and transmitted optical signals captured by adjacent photodetectors.
System Specification | Operational Parameter |
Supported Hardware | Ultrahuman Ring PRO, Ultrahuman Ring AIR |
Minimum Application Version | iOS Version 4.3.0; Android Version 3.2.0.0 |
Sensing Modality | Multi-wavelength optical photoplethysmography (PPG) |
Measurement Window | 60 seconds (requires dynamic physical immobility) |
Algorithmic Engine | FibriCheck AI/ML rhythm classification software (Qompium NV) |
Commercial Framework | On demand Heart Scan: Free for eligible members Continuous Nocturnal AFib PowerPlug: £4.90/month or £49/year (UK); €5.90/month or €49/year (EU) Cardio Adaptability PowerPlug: $2.90/month |
Geographic Availability | United States and 37 international markets (including UK, EU, UAE, Saudi Arabia, Singapore, Australia) |
The physiological geometry of the finger offers distinct diagnostic advantages over wrist based wearables because the palmar digital arteries possess higher vascular perfusion amplitude and sit closer to arterial trunks than the smaller cutaneous branches of the wrist. Nevertheless, optical signal fidelity remains vulnerable to motion artifacts. During a 60 second Heart Scan, the subject must remain stationary to avoid sensor displacement and changes in contact pressure against the dermis.
Once initiated from the Ultrahuman application dashboard, the optical sensor array captures the raw pulsatile signal and transmits the data via Bluetooth Low Energy to the host mobile device. The application securely routes the waveform to FibriCheck's processing pipeline, where automated peak-detection algorithms filter high frequency noise, remove baseline wander and extract inter beat intervals (IBI) with millisecond level precision.
Analytical Visualisations and Rhythm Classification Taxonomy
Rather than restricting user feedback to a binary output, the integration produces an exportable clinical PDF report that incorporates primary physiological waveforms and analytical plots designed for clinical review.
This reporting structure reflects standardised digital cardiology methodologies established in decentralised clinical trials such as TeleCheck AF.
Diagnostic Artifact / State | Technical Composition | Clinical Interpretation |
Raw PPG Waveform | Continuous pulse amplitude traced over 60 seconds with algorithmic peak markers | Illustrates baseline pulse morphology and signal stability. Regions degraded by movement or low perfusion are flagged as "grey zones" and excluded from analysis. |
Tachogram | Scatter plot of consecutive IBI durations in milliseconds (y-axis) across beat index $n$ (x-axis) | Sinus rhythm presents as a stable horizontal trajectory with narrow baseline variance. Arrhythmias such as AFib present as erratic vertical fluctuations across successive beats. |
Lorenz / Poincaré Plot | Cartesian scatter diagram plotting interval IBI_{n} against successive interval IBI_{n+1} | Sinus rhythm forms a tightly clustered ellipse along the line of identity (x=y). Atrial fibrillation produces a widely dispersed fan-shaped pattern, whereas ectopy generates distinct outlier clusters. |
"Regular" | Uniform peak spacing; tightly clustered Poincaré distribution | Suggests regular rhythm during the recording period. Does not rule out intermittent or transient rhythm disorders occurring outside the test window. |
"Possibly Irregular" | Variable beat intervals that deviate from regular rhythm but fail specific AFib criteria | Frequently associated with benign or symptomatic premature atrial contractions (PACs) or premature ventricular contractions (PVCs). |
"Possible Atrial Fibrillation" | Marked beat to beat variability, loss of organised pulse cadence and high entropy | Demonstrates algorithmic correlation with AFib. Directs the user to seek clinical confirmation via 12-lead electrocardiography. |
"Low Quality" / "Inconclusive" | Inadequate signal to noise ratio (>50% artifact corruption across the recording) | Triggered by movement, low peripheral perfusion, or improper ring fit; prevents erroneous rhythm classifications. |
The mathematical utility of the Lorenz plot (also known as a Poincaré plot) is central to automated rhythm triage. By evaluating non linear dynamics through the phase-space relationship:
IBI_{n+1} = f(IBI_{n})
the algorithm maps autonomic beat to beat dynamics. In healthy sinus rhythm, short term heart rate variability exhibits predictable trajectories, resulting in a narrow cluster along the diagonal line of identity. In contrast, atrial fibrillation causes chaotic atrioventricular nodal conduction characterised by elevated statistical entropy, scattering points broadly across the coordinate space and eliminating the central cluster.
Providing raw PPG waveforms alongside the tachogram and Lorenz plot allows reviewing physicians to inspect underlying pulse morphology directly. This transparency allows clinicians to distinguish true fibrillatory patterns from frequent ectopic beats or residual motion artifacts, bridging the gap between automated consumer notifications and clinical interpretation.
Physiological Synergy: Episodic Spot Checks versus Longitudinal Nocturnal Telemetry
The introduction of Heart Scan completes a dual architecture monitoring paradigm within the Ultrahuman ecosystem, uniting long term passive telemetry with short term active diagnostic capture. Passive longitudinal metrics provide insight into systemic recovery, autonomic balance and chronic cardiovascular strain. By evaluating resting heart rate (RHR) and heart rate variability (HRV) metrics, such as the root mean square of successive differences (RMSSD), Ultrahuman's Cardio Adaptability PowerPlug characterises autonomic tone and recovery patterns across successive sleep cycles.
However, exclusive reliance on nocturnal monitoring leaves an important diagnostic vulnerability unaddressed. Atrial fibrillation and supraventricular tachycardias frequently occur paroxysmally during waking hours, triggered by sympathetic surges, strenuous exertion, postprandial haemodynamic shifts, or acute emotional stress. These daytime arrhythmias often resolve before nocturnal monitoring begins, escaping detection by passive sleep-tracking algorithms.
As noted by Ultrahuman CEO Mohit Kumar, while continuous ring telemetry captures diurnal cardiovascular baselines, on demand scanning allows users to capture cardiovascular data the moment an unusual sensation occurs. Members can initiate a scan immediately following vigorous exercise, during acute stress, or upon experiencing uncharacteristic flutter or fatigue. The pairing of active spot checks with passive overnight surveillance creates a more complete surveillance framework: nocturnal monitoring establishes the physiological baseline, while episodic scans capture transient electrophysiological and haemodynamic events that might otherwise evade clinical documentation.
Regulatory Stratification and Clinical Risk Mitigation
Deploying Heart Scan highlights a common regulatory model in consumer digital health: embedding a medically cleared software algorithm into general wellness hardware. Ultrahuman markets the Ring PRO and Ring AIR as general wellness devices, exempt from premarket notification under Section 510(k) of the United States Food, Drug and Cosmetic Act when restricted to tracking general fitness, sleep and lifestyle metrics. However, software algorithms designed to analyse physiological waveforms to identify specific medical pathologies, such as atrial fibrillation, are classified as regulated medical devices (Software as a Medical Device, or SaMD).
To navigate this regulatory boundary, Ultrahuman integrated FibriCheck, developed by Qompium NV. FibriCheck maintains independent regulatory clearances:
In the United States, the software received 510(k) pre market clearance from the Food and Drug Administration under submission number K232804 within the optical camera based physiological assessment category (DXH classification), establishing statistical equivalence to traditional electrocardiography.
In the European Union, the software is certified as a Class IIa medical device under European Medical Device Regulation (MDR) standards under notified body identifier CE 1639.
This regulatory separation shapes product messaging and operational disclaimers. Ultrahuman states that Heart Scan is intended for general wellness informational screening and cannot diagnose, treat, or prevent clinical conditions. The system cannot detect myocardial ischemia or acute myocardial infarction, which require multi-lead ST-segment ECG analysis.
A "Regular" reading confirms rhythmic consistency only during that single 60 second window and does not guarantee the absence of underlying cardiac disease or paroxysmal arrhythmias. Users experiencing acute symptoms such as chest tightness, radiating pain, or severe shortness of breath must seek emergency medical care rather than relying on wearable assessments. This hybrid arrangement allows Ultrahuman to offer clinical-grade rhythm analysis while insulating its core consumer hardware from direct classification as a Class II medical device.
Diagnostic Performance, Electromechanical Limits and Comparative Clinical Efficacy
Evaluating the clinical reliability of ring-based PPG requires understanding how optical rhythm tracking compares to traditional electrocardiography. While an ECG directly measures myocardial electrical depolarisation vectors, PPG tracks the downstream mechanical pulse pressure wave generated by left ventricular ejection.
Modality / Technology | Typical Signal Source | Sensitivity for AFib | Specificity for AFib | Primary Clinical Strengths | Key Operational Limitations |
FibriCheck PPG Algorithm (Heart Scan Core) | Peripheral optical reflection (Finger/Camera) | 95.3% – 98.3% | 96.0% – 99.9% | Highly accessible; continuous or spot-check capable; requires no conductive gels or external leads. | Vulnerable to motion artifacts, ambient light leakage, and low perfusion states. |
Smartwatch PPG Screening (Pooled Meta-Analyses) | Cutaneous optical reflection at dorsal wrist | 97.4% (95% CI: 96.5–98.3) | 96.6% (95% CI: 94.9–98.3) | Broad consumer adoption; passive background monitoring during daytime and sleep. | Wrist motion frequently degrades daytime data quality, producing up to 46% uninterpretable segments. |
Single Lead Wearable ECG (e.g., Apple Watch, KardiaMobile) | Direct bi-potential electrical conduction across extremities | 83.0% – 95.0% | 88.4% – 98.0% | Direct electrophysiological recording of P-waves and QRS complexes; accepted standard for initial ambulatory confirmation. | Requires manual two-handed contact; provides only intermittent snapshots. |
12-Lead Clinical ECG (Gold Standard Reference) | Multi vector precordial and limb leads | 100% Reference | 100% Reference | Definitive diagnostic standard; maps chamber-specific vectors, axis, ischemia, and conduction blocks. | Requires clinical equipment, trained staff, and provides short-duration diagnostic capture. |
Independent clinical validation trials indicate that FibriCheck’s algorithm achieves diagnostic accuracy comparable to single-lead ECG devices when analysing high quality PPG signals, yielding sensitivity ranging from 95.3% to 98.3% and specificity from 96.0% to 99.9%. In head to head clinical testing against 12 lead ECG gold standards, overall diagnostic accuracy consistently exceeds 96%.
Despite high statistical accuracy, physiological factors can limit optical assessments. During rapid AFib runs or frequent premature ventricular contractions (PVCs), early ventricular contractions can occur before the ventricles fill adequately with blood. These contractions generate an electrical QRS complex on an ECG without generating enough stroke volume to propagate a measurable peripheral pulse wave to the finger, causing a pulse deficit where peripheral PPG heart rate estimates diverge from true electrical heart rate.
Frequent premature contractions, including premature atrial contractions (PACs) or ventricular bigeminy and trigeminy, introduce irregularities into beat to beat intervals on a tachogram that can mimic atrial fibrillation. While FibriCheck employs machine learning filters to distinguish isolated ectopy from fibrillation, high ectopic burdens can generate false positive alerts, causing unnecessary patient anxiety and downstream clinical testing.
Vasoconstriction caused by cold environments, Raynaud’s phenomenon, or peripheral vascular disease reduces blood volume shifts in digital capillary beds. Under these conditions, the ring's optical sensors receive attenuated waveforms, resulting in "Signal quality too low" or "Inconclusive" test results.
Conclusions and Industry Outlook
The introduction of Ultrahuman Heart Scan illustrates broader trends in the wearable technology and decentralised healthcare markets:
First, consumer device manufacturers are increasingly moving away from developing proprietary medical algorithms internally, opting instead to partner with specialised software providers. By integrating FibriCheck's software, Ultrahuman bypasses redundant regulatory pipelines, rapidly deploying a certified medical feature across 37 international markets.
This modular model allows consumer technology firms to focus on hardware miniaturisation, battery optimisation and industrial design, while relying on regulated third parties for clinical intelligence.
Second, the commercial structure reflects an evolving monetisation strategy. By providing on demand Heart Scan spot checks for free while charging for ongoing background monitoring via the AFib PowerPlug (£4.90 monthly in the UK) and Cardio Adaptability PowerPlug ($2.90 monthly), the company establishes a tiered commercial model. The free episodic feature drives user engagement, lowers barriers to adoption, and builds regular testing habits, while premium subscriptions monetise continuous passive background surveillance and ongoing algorithm licensing costs.
Third, generating standardised, physician readable PDF reports containing raw PPG waveforms, tachograms and Poincaré plots helps connect consumer wearables with clinical workflows. In modern cardiology programs, such as the TeleCheck AF framework, on demand wearable monitoring supports pre consultation assessments, post-ablation surveillance and anti arrhythmic drug titration. Providing clinicians with objective interval data rather than subjective patient recall reduces time to diagnosis for paroxysmal rhythm disorders.
As smart rings mature, the division between lifestyle consumer wearables and medical diagnostic platforms will continue to blur. Optical finger sensing offers advantages in user compliance and form factor, but sustained diagnostic utility depends on algorithms maintaining high specificity to prevent false positive cascades in asymptomatic populations.
The integration of FibriCheck into the Ultrahuman Ring PRO and Ring AIR establishes a functional blueprint for this transition: pairing consumer wellness metrics with certified medical software to deliver accessible, point in time cardiac surveillance.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Healthcare.Digital serves as a research platform for Nelson Advisors’ perspectives on deals, valuations and structural shifts reshaping Global Digital Health, MedTech, Healthcare AI and Health IT. https://www.healthcare.digital
Nelson Advisors is one of Europe's leading mergers and acquisitions advisory firms, exclusively dedicated to the dynamic and rapidly evolving healthcare technology sector. With a deep understanding of market dynamics and technological advancements, they empower innovative HealthTech companies and strategic investors to navigate complex transactions and achieve their growth ambitions. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #Genomics
Nelson Advisors
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments